Vitamin D and nonalcoholic fatty liver disease (NAFLD): Is it more than just an association?
暂无分享,去创建一个
[1] Fei Li,et al. FXR signaling in the enterohepatic system , 2013, Molecular and Cellular Endocrinology.
[2] D. Torres,et al. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] James E. Nelson,et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll‐like receptor activation , 2012, Hepatology.
[4] A. Vaidya,et al. The Independent Association Between 25‐Hydroxyvitamin D and Adiponectin and Its Relation With BMI in Two Large Cohorts: The NHS and the HPFS , 2012, Obesity.
[5] J. Stockman,et al. Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5 , 2012 .
[6] Leilani St Anna,et al. Clinical inquiries. Which regimen treats vitamin D deficiency most effectively? , 2011, The Journal of family practice.
[7] S. Reif,et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats , 2011, Gut.
[8] A. Kahraman,et al. Vitamin D ameliorates stress ligand expression elicited by free fatty acids in the hepatic stellate cell line LX-2. , 2011, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[9] Chao-Long Chen,et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. , 2011, Journal of hepatology.
[10] S. Morini,et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes , 2011, BMC medicine.
[11] J. Mitri,et al. Vitamin D and type 2 diabetes: a systematic review , 2011, European Journal of Clinical Nutrition.
[12] Jonathan C. Cohen,et al. Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.
[13] S. Bischoff,et al. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. , 2011, The Journal of nutritional biochemistry.
[14] V. de Lédinghen,et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.
[15] N. Chalasani,et al. Serum Vitamin D Concentrations and Unexplained Elevation in ALT Among US Adults , 2011, Digestive Diseases and Sciences.
[16] C. Housset,et al. Vitamin D and the vitamin D receptor in liver pathophysiology. , 2011, Clinics and research in hepatology and gastroenterology.
[17] G. Chrousos,et al. Hypovitaminosis D associations with adverse metabolic parameters are accentuated in patients with Type 2 diabetes mellitus: A body mass index-independent role of adiponectin? , 2011, Journal of Endocrinological Investigation.
[18] B. Clarke,et al. Vitamin D insufficiency. , 2011, Mayo Clinic proceedings.
[19] D. Brenner,et al. Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease , 2011, Gastroenterology research and practice.
[20] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[21] J. Hardies,et al. Pioglitazone in the treatment of NASH: the role of adiponectin , 2010, Alimentary pharmacology & therapeutics.
[22] R. Recker,et al. Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects , 2010, Human Genetics.
[23] H. Tilg,et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression , 2010, Gut.
[24] P. Menheere,et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[25] C. Geisler,et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells , 2010, Nature Immunology.
[26] K. Flegal,et al. Prevalence and trends in obesity among US adults, 1999-2008. , 2010, JAMA.
[27] Jian Zhang,et al. Resistin Up-Regulates COX-2 Expression via TAK1-IKK-NF-κB Signaling Pathway , 2010, Inflammation.
[28] K. Cusi. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.
[29] G. Groothuis,et al. 1α,25‐dihydroxyvitamin D3 triggered vitamin D receptor and farnesoid X receptor‐like effects in rat intestine and liver in vivo , 2009, Biopharmaceutics & drug disposition.
[30] Xiping Xu,et al. Heritability and environmental factors affecting vitamin D status in rural Chinese adolescent twins. , 2009, The Journal of clinical endocrinology and metabolism.
[31] S. Chanprasertyothin,et al. The association between vitamin D status and circulating adiponectin independent of adiposity in subjects with abnormal glucose tolerance , 2009, Endocrine.
[32] E. Tsochatzis,et al. Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy , 2009, Mediators of inflammation.
[33] S. Khalifé,et al. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. , 2009, European journal of endocrinology.
[34] P. Scherer,et al. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. , 2009, Trends in pharmacological sciences.
[35] D. Bikle. Nonclassic actions of vitamin D. , 2009, The Journal of clinical endocrinology and metabolism.
[36] D. van der Poorten,et al. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. , 2008, Clinics in liver disease.
[37] J. Ruidavets,et al. Energy intake is associated with endotoxemia in apparently healthy men. , 2008, The American journal of clinical nutrition.
[38] K. Badenhoop,et al. CYP2R1 (vitamin D 25‐hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans , 2007, Diabetes/metabolism research and reviews.
[39] G. Shulman,et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. , 2007, The Journal of clinical investigation.
[40] G. Targher,et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[41] P. Lipsky,et al. Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation , 2007, The Journal of Immunology.
[42] J. Carvalheira,et al. Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.
[43] J. Ferrières,et al. Metabolic Endotoxemia Initiates Obesity and Insulin Resistance , 2007, Diabetes.
[44] R. Recker,et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.
[45] M. Wjst,et al. A genome-wide linkage scan for 25-OH-D3 and 1,25-(OH)2-D3 serum levels in asthma families , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[46] J. Flier,et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.
[47] H. Tilg,et al. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.
[48] J. Adams,et al. Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.
[49] I. Macintyre,et al. The regulation of vitamin D metabolism , 1975, Calcified Tissue Research.
[50] C. Mathieu,et al. Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[51] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[52] G. Fantuzzi. Adipose tissue, adipokines, and inflammation. , 2005, The Journal of allergy and clinical immunology.
[53] M. Hewison,et al. Expression of 25-hydroxyvitamin D3-1α-hydroxylase in pancreatic islets , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[54] M. Hewison,et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. , 2004, The Journal of steroid biochemistry and molecular biology.
[55] Y. Takeuchi,et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.
[56] I. Campbell,et al. The plasma insulin and growth hormone response to oral glucose: Diurnal and seasonal observations in the antarctic , 1975, Diabetologia.
[57] J. Dancey,et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma , 2003, British Journal of Cancer.
[58] H. Degreef,et al. 1,25‐dihydroxyvitamin D3 inhibits ultraviolet B‐induced apoptosis, Jun kinase activation, and interleukin‐6 production in primary human keratinocytes , 2003, Journal of cellular biochemistry.
[59] Yu Wang,et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.
[60] Arya M. Sharma,et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? , 2003, The international journal of biochemistry & cell biology.
[61] T. Zimmers,et al. Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.
[62] E. Wolf,et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[63] A. Moser,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.
[64] N. Dávila,et al. Identification of a Vitamin D response element in the human insulin receptor gene promoter , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[65] N. Dávila,et al. Transcriptional activation of the human insulin receptor gene by 1,25‐dihydroxyvitamin D3 , 2002, Cell biochemistry and function.
[66] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .
[67] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.
[68] Huub F. J. Savelkoul,et al. 1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.
[69] I. Shimomura,et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[70] C. Mathieu,et al. Identification and immune regulation of 25‐hydroxyvitamin D‐1‐α‐hydroxylase in murine macrophages , 2000, Clinical and experimental immunology.
[71] H. Spiegelberg,et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. , 1995, The Journal of nutrition.
[72] D. Bikle,et al. 1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. , 1994, The Journal of biological chemistry.
[73] B. Spiegelman,et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.
[74] E. Lothman,et al. Dormancy of inhibitory interneurons in a model of temporal lobe epilepsy. , 1993, Science.
[75] M. Fanger,et al. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). , 1984, The Journal of clinical investigation.
[76] I. Macintyre. Vitamin D metabolism. , 1973, The New England journal of medicine.
[77] H. DeLuca,et al. "Activation" of vitamin D by the liver. , 1969, The Journal of clinical investigation.